Department of Health Sciences, Luleå University of Technology, 971 87 Luleå, Sweden.
Int J Pharm. 2011 Apr 4;407(1-2):63-71. doi: 10.1016/j.ijpharm.2011.01.030. Epub 2011 Jan 21.
The objective of this study was to investigate whether the miscibility of a drug and coformer, as predicted by Hansen solubility parameters (HSPs), can indicate cocrystal formation and guide cocrystal screening. It was also our aim to evaluate various HSPs-based approaches in miscibility prediction. HSPs for indomethacin (the model drug) and over thirty coformers were calculated according to the group contribution method. Differences in the HSPs between indomethacin and each coformer were then calculated using three established approaches, and the miscibility was predicted. Subsequently, differential scanning calorimetry was used to investigate the experimental miscibility and cocrystal formation. The formation of cocrystals was also verified using liquid-assisted grinding. All except one of the drug-coformers that were predicted to be miscible were confirmed experimentally as miscible. All tested theoretical approaches were in agreement in predicting miscibility. All systems that formed cocrystals were miscible. Remarkably, two new cocrystals of indomethacin were discovered in this study. Though it may be necessary to test this approach in a wide range of different coformer and drug compound types for accurate generalizations, the trends with tested systems were clear and suggest that the drug and coformer should be miscible for cocrystal formation. Thus, predicting the miscibility of cocrystal components using solubility parameters can guide the selection of potential coformers prior to exhaustive cocrystal screening work.
本研究旨在探讨药物与共晶形成剂的混溶性(由 Hansen 溶解度参数 (HSPs) 预测)是否可以指示共晶形成并指导共晶筛选。我们还旨在评估基于各种 HSPs 的混溶性预测方法。根据基团贡献法计算了吲哚美辛(模型药物)和三十多种共晶形成剂的 HSPs。然后使用三种已建立的方法计算吲哚美辛与每种共晶形成剂之间的 HSPs 差异,并预测混溶性。随后,使用差示扫描量热法研究实验混溶性和共晶形成。使用液辅助研磨也验证了共晶的形成。除了一个被预测为混溶的药物-共晶形成剂外,所有其他的药物-共晶形成剂在实验中都被证实是混溶的。所有测试的理论方法在预测混溶性方面都是一致的。所有形成共晶的体系都是混溶的。值得注意的是,在这项研究中发现了两种新的吲哚美辛共晶。尽管在广泛的不同共晶形成剂和药物化合物类型中进行这种方法的测试可能是必要的,以进行准确的概括,但测试系统的趋势是明确的,这表明药物和共晶形成剂应该是混溶的,以形成共晶。因此,使用溶解度参数预测共晶成分的混溶性可以在进行全面的共晶筛选工作之前指导潜在共晶形成剂的选择。